Companies · Biotechnology

BioNex Solutions, Inc.

SAN JOSE · Biotechnology

Diligence memoA one-page analyst read on BioNex Solutions, Inc. — recommendation, valuation, rhythm, risks.
$2.9M
Total raised · real
3
Rounds
0.9×
Latest step-up
Top 68%
Sector rank · raised
Seed
Latest stage · inferred · Fri Dec 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

BioNex Solutions, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.56× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era.
Dormant
  • Last raise 8.5 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

BioNex Solutions, Inc. is one of 4291 Biotechnology companies tracked from SAN JOSE. By capital raised it ranks in the long tail (ahead of 33% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
5
Investors (latest)
2017-12-29
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2009-07-20 Raised $510K (real) Modeled valuation $28M (est)$510K$28MPre-Seed2009Seed · 2009-07-20 Raised $1.0M (real) Modeled valuation $45M (est)$1.0M$45MSeed2009Seed · 2012-04-20 Raised $960K (real) Modeled valuation $43M (est)$960K$43MSeed2012Seed · 2017-12-29 Raised $895K (real) Modeled valuation $40M (est)$895K$40MSeed2017+$1.0M+$960K+$895KCumulative $3.4M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$510K · 2009
Seed$1.0M · 2009
Seed extension$960K · 2012
Seed extension$895K · 2017

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$39.7M
Base estimate est.
$645K
Conservative case
$311.9M
Upside case
$4.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $28.2M · 2009-07-202009Seed · modeled $44.6M · 2009-07-20Seed · modeled $42.6M · 2012-04-20Seed · modeled $39.7M · 2017-12-292017
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
8.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
34 mo
Avg between rounds
$339K/yr
Capital velocity
17.0 yr
On record since
2009
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.4× of median
This company$2.9M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.5× of median
This company$895K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.6× of median
This company$39.7M
Sector median$64.2M

Raised more than 33% of sector peers (real $). Modeled value above 41% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #139 of 175.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Kenjockety Biotechnology, LLC · Seed Raised $4.0M · modeled $177.6M (est)Mimedx Group, Inc. · Seed Raised $8.2M · modeled $177.6M (est)Helocyte, Inc. · Seed Raised $4.0M · modeled $177.5M (est)CytoDel, INC. · Seed Raised $4.1M · modeled $173.4M (est)Finch Therapeutics, Inc. · Seed Raised $4.5M · modeled $165.8M (est)Cordex Systems, Inc · Seed Raised $6.4M · modeled $164.2M (est)Viking Therapeutics, Inc. · Seed Raised $3.7M · modeled $162.3M (est)Escalier Biosciences B.V. · Seed Raised $3.5M · modeled $155.4M (est)Corino Therapeutics, Inc. · Seed Raised $3.5M · modeled $154.3M (est)BluDiagnostics, Inc. · Seed Raised $4.5M · modeled $151.0M (est)Captozyme Inc. · Seed Raised $3.4M · modeled $151.0M (est)FORGE Life Science, LLC · Seed Raised $3.6M · modeled $149.5M (est)BioNex Solutions, Inc. (this company) Raised $2.9M · modeled $39.7M (est)BioNex Solutions, Inc.
CompanyStageRaised · realValue · estvs peer med.
Kenjockety Biotechnology, LLCSeed$4.0M$177.6M2.50×
Mimedx Group, Inc.Seed$8.2M$177.6M2.50×
Helocyte, Inc.Seed$4.0M$177.5M2.50×
CytoDel, INC.Seed$4.1M$173.4M2.44×
Finch Therapeutics, Inc.Seed$4.5M$165.8M2.33×
Cordex Systems, IncSeed$6.4M$164.2M2.31×
Viking Therapeutics, Inc.Seed$3.7M$162.3M2.28×
Escalier Biosciences B.V.Seed$3.5M$155.4M2.19×
Corino Therapeutics, Inc.Seed$3.5M$154.3M2.17×
BluDiagnostics, Inc.Seed$4.5M$151.0M2.12×
Captozyme Inc.Seed$3.4M$151.0M2.12×
FORGE Life Science, LLCSeed$3.6M$149.5M2.10×
BioNex Solutions, Inc. this companySeed$2.9M$39.7M0.56×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$510K2009-07-20$2.8M$28.2M85%
Seed$1.0M2009-07-20$5.0M$44.6M85%
Seed$960K2012-04-20$4.8M$42.6M85%
Seed$895K2017-12-29$4.5M$39.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$510K2009-07-20
    • First recorded raise — entered as Pre-Seed.
    • 10 investors on this round.
  2. Seed$1.0M2009-07-20
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× larger than the prior — scaling up.
    • 14 investors on this round.
  3. Seed$960K2012-04-20
    • Raised again after 33 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 7 investors on this round.
  4. Seed$895K2017-12-29
    • Raised again after 68 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(b) (was Rule 06).
    • 5 investors on this round.
Intelligence
2020 ~Q4
Modeled next raise · ~34mo cadence
$895K
Modeled next size est.range $895K$1.4M
0.9×
Last step-up
$339K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Richard Bastiani2 other2017-12
Antonio Lima2009-07
Registry & provenance

BioNex Solutions, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1469370
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Osmol Therapeutics, Inc.BiotechnologySeed$2.9M$41.5Msame sector · same stage
TeraImmune, Inc.BiotechnologySeed$3.0M$34.1Msame sector · same stage
Sabik Medical Inc.BiotechnologySeed$3.0M$44.3Msame sector · same stage
Accuitis Inc.BiotechnologySeed$2.8M$44.4Msame sector · same stage
Curelab Oncology IncBiotechnologySeed$3.0M$40.4Msame sector · same stage
Paterna Biosciences, Inc.BiotechnologySeed$3.0M$38.9Msame sector · same stage
PhenoVista BioSciences, Inc.BiotechnologySeed$3.0M$34.6Msame sector · same stage
Precidiag, Inc.BiotechnologySeed$3.0M$39.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
BioPlx, Inc.BiotechnologySeed$47.8M91%
BioRegenx Inc.BiotechnologyPre-Seed$2.1M91%
Biogix, Inc.BiotechnologySeed$88.8M91%
BioNADrx Holdings, Inc.BiotechnologyPre-Seed$747K90%
Biodesix IncBiotechnologySeries B$635.0M90%
Bio2 Technologies, Inc.BiotechnologySeries A$16.4M89%
Synthetic Biologics, Inc.BiotechnologySeries A$36.8M89%
RegenX Science Inc.BiotechnologySeries A$62.3M89%
Frequently asked
How much funding has BioNex Solutions, Inc. raised?
BioNex Solutions, Inc. has raised approximately $2.9M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is BioNex Solutions, Inc.'s estimated valuation?
Provath's modeled valuation for BioNex Solutions, Inc. is approximately $39.7M (modeled range $645K–$311.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is BioNex Solutions, Inc. at?
BioNex Solutions, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Dec 29.
What does BioNex Solutions, Inc. do and where is it based?
BioNex Solutions, Inc. operates in the Biotechnology sector, based in SAN JOSE.
Explore related

See where BioNex Solutions, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at BioNex Solutions, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.